About
Primogene is a Leipzig-based BioTech startup specializing in the development of enzymatic biomanufacturing processes for the production of functional ingredients for nutrition and personal care, as well as pharma raw materials. Their technology aims to overcome the limitations of traditional fermentation-based approaches, enabling the cost-efficient, scalable, and sustainable production of complex biomolecules identical to their natural counterparts. The company has a strong focus on human milk oligosaccharides (HMOs), particularly disialyllacto-N-tetraose (DSLNT), and also produces fucosylated lacto-N-tetraose molecules.
Key facts
At-a-glance profile data
- Website
- primogene.com
- Headquarters
- Leipzig, Saxony, Germany
- Founded
- 2023
- Total funding
- $4M (Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Apr 2026 | Seed | $4M | High-Tech Gründerfonds (HTGF) |
Frequently asked
What does Primogene do?
Their technology extends to applications supporting gut health in adults, cognitive function in seniors, and personal care products. Primogene manages its entire production process in-house and has a robust IP portfolio. They have established commercial partnerships in the personal care sector and are actively developing pharmaceutical raw material offerings.
How much funding has Primogene raised?
Primogene has raised a total of $4M in funding. The most recent round on record is Seed.